ArticleDrug safety2026
Unveiling the Limits of Anticholinergic Burden Scales: A Study of Adverse Drug Reactions in the French Pharmacovigilance Database.
Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anticholinergic burden in community-dwelling older adults: prevalence, associated factors, and agreement between measurement scales.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and hypothesisThe anticholinergic burden is the cumulative effect of drugs with anticholinergic properties and is typically measured using one of several anticholinergic scales. We hypothesised that these scales may not fully capture all the relevant adverse drug reactions (ADRs). By accessing the French national pharmacovigilance database (FPVD) and focusing on drug classes known to induce anticholinergic ADRs, the objectives of the present study were to describe the reported ADRs, characterise the drugs involved, and examine the drugs' classification within anticholinergic scales.
methodsCases were extracted from the FPVD (1985-2024) when the suspected drug (i) had a high anticholinergic score, according to one or more of 22 anticholinergic burden scales, or (ii) belonged to the same class as the drug identified in (i). The anticholinergic ADRs investigated were confusion, glaucoma, tachycardia, urinary retention, constipation, intestinal obstruction and mydriasis.
resultsOf the 101,365 cases reported in the FPVD, regarding the selected drugs, 9629 (9.5%) involved at least one anticholinergic ADR investigated. Patients who experienced at least one anticholinergic ADR had a median age of 61 years (interquartile range: 38-79), and the majority were women (58%). Confusion was the most frequently reported anticholinergic ADR (4603 cases, of which 81% were classified as serious), followed by tachycardia (n = 1541 cases, 70% serious), and urinary retention (1061 cases, 75% serious). It is noteworthy that 98% of the 561 reported cases of intestinal obstruction were classified as serious. The drug classes with the highest number of reports were (by far) anxiolytics, antidepressants, and antipsychotics. Some drugs linked to anticholinergic ADRs in the FPVD were not present in (or were assigned a low score by) commonly used anticholinergic scales, such as the Anticholinergic Cognitive Burden.
conclusionsAnticholinergic ADRs affect both older and younger adults. The existing scoring systems might not fully capture the range of medications involved in real-world anticholinergic-related events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.